Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Aug 12, 2022

Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place...

Jul 12, 2022

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Chronic treatment with HT-ALZ (>5 weeks) demonstrated significant improvement in behavioral and cognitive function tests in an Alzheimer's disease (AD) mouse model supporting a positive...

Jun 29, 2022

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons